North American Inflammatory Bowel Disease (IBD) Market is expected to witness moderate growth registering 4.8% CAGR during the forecast period (2019-2025)

The North American IBD market is estimated to grow significantly at a CAGR of around 4.8% during the forecast period. Rising prevalence and incidence of IBD across the region is the major driving factor for the market. Moreover, an increasing number of cigarette-smokers in the US and significant funding in the IBD field in Canada is further estimated to boost the market growth of the region. Furthermore, well-developed healthcare expenditure coupled with increased per capita healthcare expenditure across the region will support the market growth over the forecast period. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per Crohn's and Colitis Canada (CCC), in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn's disease, 120,000 with ulcerative colitis, and 15,000 with IBD type unclassified (IBD-U). CCC further estimates that seven out of every 1,000 Canadians have IBD. Moreover, by 2030, the number of people living with IBD is expected to rise to over 400,000, or nearly 1% of the population.

To Request a Sample of our Report on North American Inflammatory Bowel Disease (IBD) Market: https://www.omrglobal.com/request-sample/north-american-ibd-inflammatory-bowel-disease-market

North American IBD market is segmented on the basis of disease type, diagnostics, and therapeutics. North American IBD market is segmented on the basis of disease type into ulcerative colitis and Crohn's disease. Crohn's disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn's disease than ulcerative colitis. On the basis of diagnostics, the market segmented into blood and stool, endoscopies, ultrasound, and X-rays. Endoscopy is a conventional diagnostic method that is widely being used for the diagnosis of IBD and having a considerable share in the market. The therapeutics segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.

(Get 15% Discount on Buying this Report)

A full Report of North American Inflammatory Bowel Disease (IBD) Market is Available @ https://www.omrglobal.com/industry-reports/north-american-ibd-inflammatory-bowel-disease-market

North American IBD Market Segmentation

By Disease Type

· Ulcerative Colitis

· Crohn's Disease

By Diagnostics

· Blood and Stool Tests

· Endoscopies,

· Ultrasound

· X-Ray

By Therapeutics

· Surgery

· Anti- Inflammatory Drug Administration

· Steroids

· Immunosuppressant

· Biological Drugs

· Amino salicylates

· Others

Regional Analysis

· United States

· Canada

Company Profiles

· Abbott Laboratories

· AbbVie Inc.

· Accesa Labs

· Boehringer Ingelheim International GmbH

· Celgene Corp.

· Eli Lilly and Co.

· Johnson & Johnson Services Inc.

· Laboratory Corporation of America Holdings

· Pfizer Inc.

· Sanofi S.A.

· Takeda pharmaceutical Co., Ltd.

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.